Decoy receptor 3 overexpression and immunologic tolerance in hepatocellular carcinoma (HCC) development

Cancer Investigation

Volumn 26, Issue 10, 2008, Pages 965-974

  Chen, Caixia ^a   Zhang, Changgong ^a   Zhuang, Guohong ^a   Luo, Hongfang ^a   Su, Jinhua ^a   Yin, Pinh ^a   Wang, Juan ^a  

^a XIAMEN UNIVERSITY   (China)

Author keywords

DcR3; Decoy receptor 3; Hepatocellular carcinoma; T helper cell type 2; Tumor necrosis factor receptor

Indexed keywords

CD4 ANTIGEN; CD8 ANTIGEN; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; DECOY RECEPTOR 3; FAS ANTIGEN; FAS LIGAND; FORKHEAD TRANSCRIPTION FACTOR; GAMMA INTERFERON; INTERLEUKIN 10; TRANSCRIPTION FACTOR FOXP3; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FLOW CYTOMETRY; GENE AMPLIFICATION; IMMUNOLOGICAL TOLERANCE; LIVER CELL CARCINOMA; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; TISSUE DISTRIBUTION; TUMOR GROWTH; WESTERN BLOTTING;

ACTINS; ANIMALS; ANTIGENS, CD; CARCINOMA, HEPATOCELLULAR; CELL LINE, TUMOR; DISEASE MODELS, ANIMAL; DNA PRIMERS; FAS LIGAND PROTEIN; FEMALE; FORKHEAD TRANSCRIPTION FACTORS; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; LIVER NEOPLASMS; MICE; MICE, INBRED BALB C; RECEPTORS, TUMOR NECROSIS FACTOR, MEMBER 6B; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION;

EID: 57749199956     PISSN: 07357907     EISSN: 15324192     Source Type: Journal    
DOI: 10.1080/07357900801975256     Document Type: Article

References (38)

1. Migone, T.S.; Zhang, J.; Luo, X.; Zhuang, L.; et al. TL1A is a TNF-like ligand for DR3 and TR6/DcR3 and functions as a T cell costimulator. Immunity 2002, 16, 479-92.
2. Hayashi, S.; Miura, Y.; Nishiyama, T.; et al. Decoy receptor 3 expressed in rheumatoid synovial fibroblasts protects the cells against Fas-induced apoptosis. Arthritis Rheum 2007, 56, 1067-1075.
3. Pitti, R.M.; Marsters, S.A.; David, A., et al. Genomic amplification of a decoy receptor for Fas ligand in lung and colon cancer. Nature 1998, 396, 699-703.
4. Shen, H.W.; Wu, Y.L.; Peng, S.Y.; et al. Overexpression and genomic amplification of decoy receptor 3 in hepatocellular carcinoma and significance thereof. Zhonghua Yi Xue Za Zhi 2003 , 83, 744-747.
5. Chang, Y.C.; Hsu, T.L.; Lin, H.H.; et al.Modulation of macrophage differentiation and activation by decoy receptor 3. J Leukoc Biol 2004, 75, 486-494.
6. Tsui-Ling, H.; Ying-Yu, W.; Yung-Chi, C.; et al. Attenuation of Th1 Response in Decoy Receptor 3 Transgenic Mice. J Immunol, 2005, 175, 5135-5145.
7. Tokumasa, N.; Suto, A.; Kagami, S.I.; et al. Expression of Tyk2 in dendritic cells is required for IL-12, IL-23, and IFN-gamma production and the induction of Th1 cell differentiation. Blood 2007.
8. Wortinger, M.A.; Foley, J.W.; et al. Fas ligand-induced murine pulmonary in̄ammation is reduced by a stable decoy receptor 3 analogue. Immunol 2003, 110, 225-233.
9. Suda, T.; Takahashi, T.; Golstein P.; Nagata, S. Molecular cloning and expression of the Fas ligand, a novel member of the tumor necrosis factor family. Cell 1993, 75, pp. 1169-1178.
10. Manicassamy, S., Sun Z. The critical role of protein kinase C-theta in Fas/Fas ligand-mediated apoptosis. J Immunol 2007 Jan 1; 178(1):312-319.
11. Matute-Bello, G.; Liles, W.C.; Frevert, C.W.; et al., Blockade of the Fas/FasL system improves pneumococcal clearance from the lungs without preventing dissemination of bacteria to the spleen. J Infect Dis 2005 Feb 15; 191(4):596-606.
12. Fecci, P. E.; Mitchell, D. A.; Whitesides, J. F.; et al. Increased regulatory T-cell fraction amidst a diminished CD4 compartment explains cellular immune defects in patients with malignant glioma. Cancer Res 2006, 66, 3294-3302.
13. + regulatory T cells in patients treated with high-dose interleukin-2 for metastatic melanoma or renal cell carcinoma. J Clin Oncol 2006, 24, 1169-1177.
14. + regulatory T cell in the patients with ovarian carcinoma. Cancer Invest 2005, 23, 399-403.
15. Curiel, T.J.; Coukos, G.; Zou, L.; et al. Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival. Nat Med 2004, 10, 942-949.
16. Wolf, D.; Wolf, A.M.; Rumpold, H.; et al. The expression of the regulatory T cell-specific forkhead box transcription factor FoxP3 is associated with poor prognosis in ovarian cancer, Clin Cancer Res 2005, 11, 8226-8229.
17. + regulatory T cells. J Exp Med 2005, 201, 1061-1067.
18. + regulatory T cells in human thymus. Nature 2005, 436, 1181-1185.
19. + regulatory T cells by TGF-beta induction of transcription factor Foxp3. J Exp Med 2003, 198, 1875-1886.
20. + regulatory T cells responsible for protection against diabetes. Proc Natl Acad Sci USA 2004, 101, 4572-4577.
21. + regulatory T cells by copolymer-I through activation of transcription factor Foxp3. Proc Natl Acad Sci USA 2005, 102, 6449-6454.
22. + T regulatory cells. Nat Immunol 2003, 4, 337-342.
23. Hori, S.; Nomura, T.; Sakaguchi, S. Control of regulatory T cell development by the transcription factor Foxp3. Science 2003, 299 1057-1061.
24. + regulatory T cells. Int Immunol 2004, 16, 1643-1656.
25. Cellular and molecular immunology In: A.K. Abbas, A.H. Lichtman and J.S. Pober, (eds). Philadelphia (PA): WB Saunders Company.1994; 315-346.
26. Valente, G.; Ozmen, L.; Novelli F.; Geuna, M.; Palestro, G.; Forni, G.; Garotta, G. Distribution of interferon- receptor in human tissues. Eur J Immunol 1992, 22:2403.
27. Farrar, M.A.; Schreiber, R.D. The molecular cell biology of interferon- and its receptor. Annu Rev Immunol 1993, 11:571.
28. Langaas, V.; Shahzidi, S.; Johnsen, J.I.; Smedsrod, B.; Sveinbjornsson B. Interferon-modulates TRAIL-mediated apoptosis in human colon carcinoma cells. Anticancer Res 2001, 21:3733.
29. Mazzolini, G.; Narvaiza, I.; Martinez-Cruz, L.A.; Arina, A.; Barajas, M.; Galofre, J.C.; Qian, C.; Mato, J.M.; Prieto, J.; Melero, I. Pancreatic cancer escape variants that evade immunogene therapy through loss of sensitivity to IFN-induced apoptosis. Gene Ther 2003, 10:1067.
30. Dighe, A.S.; Richards, E.; Old, L.J.; Schreiber, R.D. Enhanced in vivo growth and resistance to rejection of tumor cells expressing dominant negative IFN-γ receptors. Immunity 1994, 1, 447.
31. Basham, T.Y., Merigan, T.C. Recombinant interferon-γ increases HLA-DR synthesis and expression. J Immunol 1983, 130:1492.
32. Houghton, A.N.; Thomson, T.M.; Gross, D.; Oettgen, H.F.; Old, L.J. Surface antigens of melanoma and melanocytes: specificity of induction of Ia antigens by human γ-interferon. J Exp Med 1984, 160, 255.
33. Brunda, M.J.; Rosenbaum, D. Modulation of murine natural killer cell activity in vitro and in vivo by recombinant human interferons. Cancer Res 1984, 44, 597.
34. Wang, T.; Niu, G.; Kortylewski, M.; Burdelya, L.; Shain, K.; Zhang, S.; Bhattacharya, R.; et al. Nat Med 2004, 10, 48-54.
35. Sato, T.; McCue, P.; Masuoka, K.; Salwen, S.; Lattime, E.C.; Mastrangelo, M.J.; Berd, D. Interleukin 10 production by human melanoma. Clin Cancer Res 1996, 2, 1383-1390.
36. Patel, K.B.; Berd, D.; Mastrangelo, M.J.; Terai, M.; Sato, T. Prognostic importance of interleukin-10 (IL-10) production by metastatic melanoma tissues from patients receiving autologous vaccine therapy. Proceedings ASCO 2002, 432.
37. Koli, K.M.; Arteaga, C.L. Complex role of tumor cell transforming growth factor (TGF)-beta s on breast carcinoma progression. J. Mammary Gland Biol. Neoplasia 1996, 1, 373-380.
38. Y. Oh; Muller, H.L.; Ng L.; Rosenfeld, R.G. Transforming growth factor-beta-induced cell growth inhibition in human breast cancer cells is mediated through insulin-like growth factor-binding protein-3 action, J Biol Chem 1995, 9, 13589-13592.